Hepatoblastoma
Clinical Trials
Last Updated October 30, 2026While clinicians and care teams remain your best resource for navigating treatment options, this platform allows families to search current studies, eligibility criteria, and emerging therapies nationwide to help guide informed discussions with their medical team.
Hepatoblastoma Clinical Trials Count Me In (CMI), an initiative focused on patient-partnered cancer research, has announced the launch of a new cohort for individuals with hepatocellular carcinoma (HCC) and HCC-like tumors. Due to the rarity of these tumors, only a small number of patients have previously been in a position to provide their samples and clinical data for cancer research, until now.
Count Me In
The IMPACT clinical trial (Immunotherapy for Solid Tumor Malignancies in Pediatrics using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T cells) is a Phase 1 clinical trial conducted by Seattle Children’s. The main goal of this study is to evaluate the safety and feasibility of a specialized type of immunotherapy known as CAR T-cell therapy for children and young adults diagnosed with specific GPC3-positive solid tumors (such as certain soft tissue, liver, and kidney malignancies) after they receive lymphodepleting chemotherapy.
IMPACT
Recent progress by researchers at Texas Children’s, Baylor College of Medicine and Seattle Children’s was published in the New England Journal of Medicine. Study shows that children with advanced, treatment-resistant hepatoblastoma achieved complete remission following novel cellular immunotherapy—marks an incredible step forward in proving that immunotherapy can successfully target solid pediatric tumors. This progress offers a powerful new source of hope, signaling that innovative, less toxic options are beginning to emerge.
CAR-T Cell Therapy
The Paediatric Hepatic International Tumour Trial (PHITT) for hepatoblastoma and hepatocellular carcinoma officially closed to recruitment on December 31, 2023.
Final trial results and published data are expected to take approximately 2 to 3 years after closure (projected around 2026–2027)
PHITT Study
The ARYA-2 study is a clinical trial testing an experimental immunotherapy called ET140203 ARTEMIS® T-cell therapy for children and teens with advanced, relapsed, or hard-to-treat liver cancers, including Hepatoblastoma and HCC. It uses specially engineered T-cells to target cancer cells, and eligible participants will need to test positive for specific biomarkers (AFP and HLA-A2).
Eureka Therapeutics
The CARE study is an early-phase clinical trial testing an experimental immunotherapy that uses a child's own modified immune cells—called "CARE T cells"—to target and fight solid tumors like pediatric liver cancers. It is primarily designed for children and young adults whose cancer has relapsed, hasn't gone away with standard treatment, or for whom standard options aren't available, to evaluate the safety and effectiveness of this new cellular approach.
CARE Study
Please Note: Information provided on HRN's website is for educational and community-sharing purposes only. HRN is a patient- and family-focused community network, not a medical organization or clinical provider. Content listed here should not be taken as medical advice or a recommendation to join a specific study. Please discuss all clinical trials and treatment decisions directly with your primary medical team.